Message board

News

Symposium Gynaecologic pelvine oncology: 'From evidence to reality'

On Wednesday November 25th, 2026 the first symposium of Gynaecologic Pelvine Oncology will take place. The goal of this symposium is to gather health care professionals to translate new insights in…

News

Avutometinib and Defactinib Show Significant Activity in LGSOC

An international phase II study led by Verastem demonstrates that the combination of avutometinib and defactinib has a significant effect on response rate, duration of response, and progression-free…

News

New Study Confirms Beneficial Effect of Relacorilant

An international phase III study conducted by Corcept demonstrates that the combination of relacorilant and nab-paclitaxel results in a statistically significant improvement in progression-free…

News

Pembrolizumab Improves Disease-Free Survival in dMMR Endometrial Carcinoma

A randomized double-blind phase III study conducted by Merck Sharp & Dohme demonstrates that adding pembrolizumab to first-line chemotherapy does not improve disease-free survival in the overall…

News

New treatment successfull in therapy-resistant ovarian cancer

An international trial, led by UZ Leuven, shows that ovarian cancer patients treated with an antibody combined with chemotherapy have a longer survival compared to patients treated with standard…

News

Immunotherapy Combined with Chemotherapy Improves PFS in Endometrial Carcinoma

An international phase III study led by AstraZeneca demonstrates that adding durvalumab to standard chemotherapy followed by maintenance therapy with durvalumab, with or without olaparib,…

News

Tisotumab Vedotin Represents a Promising Treatment Approach in Cervical Cancer

An international phase Ib/II study led by Genmab demonstrates that tisotumab vedotin combined with bevacizumab, pembrolizumab, or carboplatin shows promising activity in cervical cancer. The study…

News

Genetic test determines maintenance treatment for ovarian cancer

Researchers in Leuven develop a genetic test to determine in which patients a maintenance treatment with PARP inhibitors would be effective

News

Therapy resistance in ovarian cancer unraveled

Ovarian cancer can usually be treated effectively with platin-based treatments, but over time nearly all patients do relapse because the tumour cells become resistant. A preclinical trial led by UZ…